NCT04102202撤回1 期
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel-Groups, Safety & Efficacy Trial of BOL-DP-o-05 as an Add-On Treatment for Preservation of Beta-Cell Function in Subjects With Newly-Diagnosed T1DM
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 主要终点
- To evaluate the effect of BOL-DP-o-05 on preservation of beta-cell function
研究概览
简要总结
BOL-DP-o-05 as an Add-On Treatment for Preservation of Beta-Cell Function in Subjects With Newly-Diagnosed Type 1 Diabetes Mellitus (T1DM)
详细描述
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Groups study in which subjects will be randomized to receive either BOL-DP-o-05 or placebo as an Add-On Treatment. The study evaluates the effect of BOL-DP-o-05 for Preservation of Beta-Cell Function in Subjects with Newly-Diagnosed Type 1 Diabetes Mellitus (T1DM). The study includes a screening period up to three weeks followed by a 48-week treatment period
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 5 Years 至 30 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed consent obtained before any trial-related activities.
- •T1DM ≤ 20 weeks prior to screening.
- •Male or female, aged 5-30 years old (both inclusive) at the time of signing the informed consent form.
- •Non-fasting peak C-peptide ≥0.2 nmol/l during mixed-meal tolerance test (MMTT) at Visit
- •BMI ≥18.5 kg/m
- •Presence of one or more islet-specific autoantibodies at the screening.
- •Insulin dependence, unless in temporary spontaneous remission ("honeymoon period").
排除标准
- •Daily insulin usage > 1 U/kg per day at screening
- •History of recurrent (e.g. several times a year) of severe (e.g. pneumonia) or chronic infections or conditions predisposing to chronic infections.
- •History of severe systemic fungal infection within the past 12 months prior to screening unless treated and resolved with appropriate documented therapy.
- •Vaccination within 4 weeks before randomization.
- •Receipt of any other concomitant medications or herbal products that can influence the immune system within 90 days prior to screening.
- •History of pancreatitis (acute or chronic).
- •Any past or current diagnosis of malignant neoplasms.
- •Known impairment of the immune system, except for T1DM, coeliac disease, alopecia, autoimmune antibodies not considered clinical important (e.g. thyroid antibodies without any clinically important thyroid disease), and vitiligo.
- •Patients with a psychiatric condition (e.g. severe anxiety, psychosis) that would interfere with the study as determined by the primary investigator.
- •Patients with known allergy to one or more of the study drug components.
- •Female patients who are pregnant, lactating, or who want to get pregnant during the study period. In the case of young patients, the PI should raise this point with the patient/family.
- •Male subjects who want their partner to get pregnant.
- •Female of child-bearing potential who do not agree to utilize medically acceptable and reliable means of birth control during the study and for 1 month following the last dose of the study unless the patient is young and the PI speaks with the patient/family and waived the criteria due to young age.
- •Patients with a history of alcohol or any psychoactive substance abuse or dependence (including alcohol but excluding nicotine and caffeine).
- •Patients with a first-degree family history of a psychiatric condition diagnosed at age<30 years.
- •Patients with congestive heart failure or any other chronic disease.
- •Patients with heart failure, psychotic state in the past, anxiety disorder, and heredity significant psychiatric inheritance in first-degree family relative, especially in patients younger than 30, and a history of addiction or drug abuse.
研究组 & 干预措施
BOL-DP-o-05
Experimental
干预措施: BOL-DP-o-05 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
To evaluate the effect of BOL-DP-o-05 on preservation of beta-cell function
时间窗: up to week 48
Plasma levels of C-peptide concentration
次要结局
- Number of diabetic ketoacidosis episodes(Through study completion, an average of 48 weeks)
- Number of severe hypoglycaemic episodes(Through study completion, an average of 48 weeks)
- To assess the change in HbA1c(Baseline to weeks 24 and 48)
- To evaluate total daily insulin dose(Week 24 and week 48)
- To Assess the percentage of patients that maintain stimulated peak C-peptide ≥ 0.2nmol/L(At week 48)
- Peak MMTT stimulated C-peptide concentration(Base line and week 48)
- To assess the change in fasting C-peptide(Baseline to week 24 and week 48)
- To Assess the percentage of patients that achieve glycemic target of HbA1c ≤ 7.5%(At week 24 and week 48)
- To assess the percent of subjects who require a daily insulin dose < 0.5 IU/kg body weight(After 12 months of first treatment)
研究者
相似试验
已完成
3 期
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes AdultsType 1 Diabetes MellitusNCT01103284Andromeda Biotech Ltd.475
已完成
3 期
Empagliflozin and the Preservation of Beta-cell Function in Women with Recent Gestational DiabetesGestational DiabetesNCT03215069Mount Sinai Hospital, Canada91
已完成
1 期
Beta Cell Function and Related Pharmacodynamics of HMS5552 in T2DM PatientsType 2 DiabetesNCT02386982Hua Medicine Limited24
已完成
2 期
Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 DiabetesType 1 DiabetesNCT00998699XOMA (US) LLC22
已完成
不适用
Preservation of Beta-cell Function in Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT00232583University of Texas Southwestern Medical Center58